Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 11/20 | 0.32 |
| ▸ | APLNR | P35414 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan SCHEMBL17181203 | 0.94 | GHSR (0.42) | GHSR | |
| Phenylalanine SCHEMBL1239600 | 0.93 | GHSR (0.35) | GHSRRENAPLNR | |
| Phenylalanine SCHEMBL1239317 | 0.89 | ANPEP (0.33) | APLNR | |
| Phenylalanine SCHEMBL1239320 | 0.87 | ANPEP (0.36) | — | |
| Tryptophan SCHEMBL17181205 | 0.86 | GHSR (0.44) | GHSR | |
| Arginine SCHEMBL28048007 | 0.81 | KDM1A (0.34) | GHSRAPLNR | |
| Histidine SCHEMBL8428513 | 0.81 | — | — | |
| Phenylalanine SCHEMBL294178 | 0.80 | REN (0.36) | REN | |
| Arginine SCHEMBL29238661 | 0.80 | APLNR (0.39) | GHSRAPLNR | |
| Glutamic Acid SCHEMBL6661749 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297669-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | SOCIEDADE BENEFICENTE DE SENHORAS HOSPITAL SIRIO LIBANES (BR) | 2015-10-22 | — | — | US | claimed |
| US-20130196904-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | SOCIEDADE BENEFICENTE DE DENORAS HOSPITAL SIRIO LIBANES (BR) | 2013-08-01 | — | — | US | claimed |
| EP-2459207-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | SOCIEDADE BENEFICENTE DE SENHORAS HOSPITAL SÍRIO E LIBANÊS (BR) | 2012-06-06 | — | — | EP | claimed |
| WO-2011011847-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | SOCIEDADE BENEFICIENTE DE SENHORAS HOSPITAL SIRIO LIBANES (BR) | 2011-02-03 | — | — | WO | claimed |
| US-9452196-B2 | Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases | SOCIEDADE BENEFICENTE DE SENHORAS HOSPITAL SIRIO LIBANES (BR) | 2016-09-27 | — | — | US | disclosed |
| US-20150297669-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | SOCIEDADE BENEFICENTE DE SENHORAS HOSPITAL SIRIO LIBANES (BR) | 2015-10-22 | — | — | US | disclosed |
| US-20140296153-A1 | Oligodendrocyte Differentiation | ALVES XAPELI SARA (PT) | 2014-10-02 | — | — | US | disclosed |
| EP-2741759-A2 | OLIGODENDROCYTE DIFFERENTIATION | University Of Coimbra (PT) | 2014-06-18 | — | — | EP | disclosed |
| EP-2459207-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING OBESITY, DIABETES OR TO INCREASE INSULIN SENSITIVITY | SOCIEDADE BENEFICENTE DE SENHORAS HOSPITAL SIRIO E LIBANES (BR) | 2013-11-20 | — | — | EP | disclosed |
| US-20130196904-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | SOCIEDADE BENEFICENTE DE DENORAS HOSPITAL SIRIO LIBANES (BR) | 2013-08-01 | — | — | US | disclosed |
| WO-2013021196-A2 | OLIGODENDROCYTE DIFFERENTIATION | UNIVERSITY OF COIMBRA (PT) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297669-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | GIPR, GPR119, GLP1R | GHSR 32/4885REN 209/4885APLNR 127/4885 |
| US-20130196904-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES | GIPR, GPR119, GLP1R | GHSR 34/4885REN 207/4885APLNR 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.